Clinical Course of Factor VIII Inhibitors Developed after Exposure to a Pasteurised Dutch Concentrate Compared to Classic Inhibitors in Hemophilia A

Summary

After the introduction of a new pasteurised factor VIII concentrate (Factor VIII CPS-P) in The Netherlands in June 1990, an increase in the occurrence of inhibitors in hemophilia A patients was reported. The clinical course of this group of inhibitors (n = 12) was compared with hemophilia patients in whom an inhibitor developed before June 1990 (classic inhibitors) (n = 32). Striking differences were found between both groups not only in patient age (median 22 years versus 8 years) and number of exposure days (<50 − >1000 versus <50), as described in previous reports, but also in clinical course and response to treatment. In the recent group of inhibitors antibody titers showed a rapid decline when product was changed which was not the case in the group with classic inhibitors. In the group of classic inhibitors immune tolerance therapy with low dose factor VIII succeeded in 83%. Success was to a high degree dependent on the inhibitor level. In the group of recent inhibitors immune tolerance with the same concentrate was only successful in a single patient. However, once the patients were switched to another concentrate, antibody levels dropped to less than 2 BU/ml within 8 months in all patients.

It seems likely that in this group of product associated inhibitors, treatment success was due to elimination of antigen stimulation rather than induction of immune tolerance.

• References

• 1 Schwarzinger I, Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Haematol 1987; 24: 241-5
• 2 Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-71
• 3 Ehrenfort S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhadt B, Kornhuber B. Incidence of development of factor VIII and IX inhibitors in haemophiliacs. Lancet 1992; 339: 554-8
• 4 Lusher JM, Salzman PM. and the Monoclate study group. Viral safety and inhibitor development associated with factor VIII C ultra-purified from plasma in hemophiliacs previously unexposed to factor VIII C concentrates. Semin Hematol 1990; 27 Suppl (Suppl. 02) 1-7
• 5 Sultan Y. and the French hemophilia study group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2
• 6 Mc Millan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. and the hemophilia study group. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8
• 7 Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984; 150: 19-29
• 8 Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-5
• 9 Rosendaal FR, Nieuweiihuis HK, van den Berg HM, Heijboer H, Mauser-Bunscholen EP, Van der Meer J, Smit C, Strengers PFW, Briet E. and the Dutch hemophilia study group. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 1993; 81: 2180-6
• 10 Peerlinck K, Arnnnt J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8
• 11 van Leeuwen EF, Mauser-Bunschoten EP, van Dijken PJ, Kok AJ, Sjamsoedin-Visser EJM, Sixma JJ. Disappearance of factor VIILC antibodies in patients with haemophilia A upon frequent administration of FVIII in intermediate or low dose. Br J Haematol 1986; 64: 291-7
• 12 Mauser-Bunschoten EP, Nilsson IM, Kasper CK. Immune tolerance: A 1990 approach. In: Hemophilia and von Willebrand’s disease in the 1990’s. Lusher JM, Kessler CM. eds Excerpta Medica 1991: 265-9
• 13 Over J, Sixma JJ, Doucet-De Bruïne MHM, Trieschnigg AMC, Vlooswijk AA, Beeser-Visser NM. Survival of 125 Iodine-labeled factor VIII in normals and patients with classic hemophilia. J Clin Invest 1978; 62: 223-34
• 14 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, Mc Millan CW, Pool JG, Shapiro SS, Schulman NR, van Eijs J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72
• 15 Bouma BN, Starkenborg AE. Dilution of hemophilia plasma used as a reagent in the determination of anti-hemophilia factor A (Factor III). Hameost 1974; 3: 94-7
• 16 Lee ML, Gomperts ED, Kingdon HS. A note on the calculation of recovery for factor VIII infusions. Thromb Haemost 1993; 69: 87
• 17 Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-81
• 18 Mantel N. Evaluation of survival data and two new rank orders statistics arising in its consideration. Cancer Chemther Rep 1966; 50: 163-70
• 19 Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, Cyclophosphamide and Factor VIII. New Engl J Med 1988; 318: 947-50
• 20 Ewing NP, Sanders NL, Dietrich SL, Kasper CK. Induction of immune tolerance to Factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65-8
• 21 Aznar JA, Jorquera JI, Peiro A, Garcia I. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A. Tlnoinb Haemost 1984; 51: 217-21
• 22 Sultan Y, Maisonneuve P, Kazatchkine MD, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor Vlll (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2: 765-8
• 23 Gilles JGG, Arnout J, Peerlinck Vermijlen J, Saint Remy JMR. A sudden outbreak of inhibitors during treatment with a particular pasteurized factor VIII concentrate (FVIII-CPS-P): Characterization of specific antibodies. Thromb Haemost 1993; 69: 557
• 24 Benny AG, Scott RH, Woodfield DG. A heat-treated factor VIII concentrate prepared by controlled-pore glass adsorption chromatography. Transfusion 1987; 27: 174-7
• 25 Hiemstra H, Nieuweboer CEF, Idoe MA, Claassen JE, Vos AHV, Tersmette M, Strengers PFW, Over J, Mauser Bunschoten EP, Heijboer H, Holdrinet ACJM. Evaluation of wet pasteurization of a factor VIII concentrate produced by controlled-pore silica adsorption. Folia Haematol 1990; 4: 557-63
• 26 Barrowcliffe W, Kemball-Cook G, Tubbs JE. Inhibitor development and activated Factor VIII in concentrates. Thromb Haemost 1993; 70: 1065-6